Reps. Davis, Tenney push for genetically targeted heart disease technologies
Key takeaways
- Explaining how improving access to GTTs would benefit constituents, Davis said, At the end of the day, when you re able to get advanced medications out there, patients are going to benefit.
- I mean, that s huge especially in rural American areas like where I serve in eastern North Carolina, he added.
- If passed, the MINI Act would require that GTTs have market approval for at least 11 years before becoming eligible for Medicare negotiation.
Why this matters: political developments that affect policy direction and public trust.
Don Davis (D-N.C.) and Claudia Tenney (R-N.Y.) on Thursday said the House is prepared to pass legislation supporting wider access to genetically targeted technologies (GTT) that can treat conditions like heart disease, with the current challenge being to get it on the front burner in the Senate.
Appearing at The Hill s Protecting Patients from America s Number One Killer event, Davis and Tenny discussed their bill titled the Maintaining Investments in New Innovation (MINI) Act, which would legislate when genetically targeted technologies can be eligible for Medicare drug price negotiation.
The Alliance for Patient Access describes GTTs as generally delivered via injection, and something that clinicians treat patients once or twice a year in a medical office rather than patients needing to take daily medication at home.